Trials / Completed
CompletedNCT04877431
A Study of Teduglutide (Revestive®) in Children, Teenagers and Adults With Short Bowel Disease
Post Authorization Study to Monitor Efficacy, Effectiveness and Safety of Teduglutide (Revestive®) in Adult and Pediatric Patients With Short Bowel Syndrome in Argentina
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 45 (actual)
- Sponsor
- Takeda · Industry
- Sex
- All
- Age
- 1 Year
- Healthy volunteers
- Not accepted
Summary
The main aims of the study are to assess the safety profile of Teduglutide (Revestive®) in people with Short Bowel Disease as well as how well people respond to the treatment with Teduglutide (Revestive®). This study is about collecting data only; participants receive Teduglutide (Revestive®) by their doctors according to the clinical practice but not as part of this study. Only standard care information available in the participant's medical records will be reviewed and collected for this study. Participants do not need to visit their doctor in addition to their normal visits.
Conditions
Timeline
- Start date
- 2020-11-05
- Primary completion
- 2023-06-05
- Completion
- 2023-06-05
- First posted
- 2021-05-07
- Last updated
- 2023-07-19
Locations
1 site across 1 country: Argentina
Source: ClinicalTrials.gov record NCT04877431. Inclusion in this directory is not an endorsement.